CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1

Sorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma (HCC). However, sorafenib resistance significantly limits its therapeutic efficacy, and the mechanisms underlying resistance have not been fully clarified. Here we report that a circular RNA, circRNA-SORE (a c...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Signal Transduct Target Ther
Päätekijät: Xu, Junjie, Ji, Lin, Liang, Yuelong, Wan, Zhe, Zheng, Wei, Song, Xiaomin, Gorshkov, Kirill, Sun, Qiming, Lin, Hui, Zheng, Xueyong, Chen, Jiang, Jin, Ren-an, Liang, Xiao, Cai, Xiujun
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7762756/
https://ncbi.nlm.nih.gov/pubmed/33361760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41392-020-00375-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia